Jefferies Downgrades Bristol Myers Squibb and Cuts Estimates (BMY)

Jefferies Downgrades Bristol Myers Squibb and Cuts Estimates (BMY)


Jefferies announced on Friday that it has lowered its rating on biopharmaceutical company Bristol Myers Squibb Co. (BMY).

The firm has downgraded BMY from a “Buy” to a “Hold,” and has given the company a $49 price target. This price target suggests a 7% upside from the stock’s current price of $45.63.

Analysts believe that the stock’s valuation is fair based on nivolumab strength. Despite its strength, analysts believe that “other areas of the business including the diabetes franchise and the Eliquis launch are not faring so well, which has led to some significant cuts in our revenue and EPS estimates.”

Jefferies has reduced estimates on the company by 9-10% based on lower expected revenue from Eliquis, Onglyza, Bydureon and Byetta.

Bristol Myers Squibb shares were down 41 cents, or 0.89% during Friday morning trading. The stock is up 40% YTD.

The Bottom Line
Shares of Bristol Myers Squibb Co. (BMY) have a 3.08% yield, based on Friday morning’s price of $45.42.

Bristol Myers Squibb Co. (BMY) is a “Recommended” dividend stock at this time, holding a DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Free Updates

Join over 100,000 investors who get the latest news from

Best Dividend Stocks

Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the:

Best Dividend Stocks

Partner Center

Best CD Rates

Sitting on some extra cash and looking for the most current and profitable CD Rates?

Get The Best CD Rates

14 Day Free Trial

Earn more from your dividend portfolio within the next 14 days.

Sign Up Today